Bevespi (Glycopyrrolate)

Generic Name

Glycopyrrolate

Brand Names

Bevespi, Cuvposa, Glycate, Glyrx-Pf, Prevduo, Trimbow

FDA approval date: September 30, 1990

Classification: Cholinergic Muscarinic Antagonist

Form: Injection, Aerosol, Tablet, Liquid, Solution

What is Bevespi (Glycopyrrolate)?

BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease . Limitations of Use: BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Double-dummy, Double-blind, Randomized, Active Controlled, Two-way Cross-over Study With 12 Week Treatment Duration Period, to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Compared to Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Enrollment Status: Recruiting

Publish Date: August 26, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The purpose of this study is to evaluate the efficacy and safety of indacaterol acetate / glycopyrronium bromide / mometasone furoate (QVM149) compared to salmeterol xinafoate / fluticasone propionate in children from 12 to less than 18 years of age with asthma with pre-bronchodilator FEV1 ≥ 50 % of the predicted normal value for the participant.

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

Enrollment Status: Recruiting

Publish Date: August 21, 2026

Intervention Type: Drug

Summary: The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treati...

A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Bromide) in Children From 6 to Less Than 12 Years of Age With Asthma.

Who is this study for: Children from 6 to less than 12 years of age with asthma

Enrollment Status: Recruiting

Publish Date: August 19, 2026

Intervention Type: Drug

Study Drug: Glycopyrronium bromide

Study Phase: Phase 2

Summary: The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo. Outcome of this study will be used to determine the dose of inhaled glycopyrronium for the development of fixed dose combination indacaterol/mometasone/glycopyrronium (QVM149) for children aged 6 to less than 1...

View All Clinical Trials